Pharmaceutical Industry Articles & Reports - Page 13

Compare leading AI HCP engagement platforms for pharma commercial operations. Review the 2026 capabilities of Aktana, OptimizeRx, Pega, and Veeva Vault CRM.

Analyze how AI clinical trial recruitment addresses enrollment bottlenecks. This report examines Iterative Health's $77M expansion into cardiology and obesity.

Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.

Analyze Pfizer's $10B acquisition of Metsera and the evolving GLP-1 obesity drug market. Learn about competing pipelines, clinical data, and pharma strategy.

Analyze the 2026 FDA Accelerated AI Pathway Pilot. Review the regulatory framework and the 10 selected companies advancing AI-discovered drugs to Phase I.

Review the FDA approval of relacorilant (Lifyorli) for platinum-resistant ovarian cancer. Learn its clinical efficacy and mechanism as a GR antagonist.

Examine how AI-driven ultra-large virtual screening evaluated 325 billion molecules to identify MDL-4102, a highly selective BRD4 inhibitor for oncology.

Review the 2026 FDA approval of Optune Pax (TTFields) for locally advanced pancreatic cancer. Explore PANOVA-3 trial survival data and mechanism of action.

Examine how leading pharmaceutical companies utilize AI training and workforce upskilling programs to address digital skill gaps in drug discovery operations.

Analyze 2027 drug patent expirations and the impending patent cliff. Review a detailed loss-of-exclusivity (LOE) calendar for biologics and small molecules.

Examine LLM security risks in pharma, including prompt injection and data exfiltration. Review red teaming methods and GxP risk assessments for regulated AI.

Examine the 2026 FDA real-time clinical trial pilot. This report analyzes how AI and cloud platforms enable continuous oncology data monitoring for new drugs.

Examine the May 2026 White House MFN drug pricing policy. Learn how 17 bilateral pharma agreements and the TrumpRx initiative project $529B in U.S. savings.

Learn about the FDA's new HALO platform and Elsa 4.0 AI system. This guide covers consolidated eCTD submissions, AI review workflows, and sponsor migration.

Examine the April 2026 FDA approval of Idvynso (doravirine/islatravir). Understand this tenofovir-free, two-drug HIV regimen's clinical efficacy and safety.

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

Review AstraZeneca's tozorakimab Phase 3 MIRANDA trial results for COPD. This analysis explains IL-33 pathway biology and compares itepekimab clinical data.

Review this educational playbook for Veeva CRM Approved Email implementation. Learn about technical setup, compliance frameworks, HCP engagement, and pitfalls.

Examine AI in pharma HEOR and real-world evidence. This report details how machine learning and RWD advance health economic modeling and regulatory decisions.

Review the FDA full approval of Tecartus for relapsed mantle cell lymphoma. This analysis covers ZUMA-2 Cohort 3 efficacy data, CAR-T safety, and clinical use.

Review the Veeva Vault 26R2 release preview. Learn about mid-2026 platform enhancements, including document viewer upgrades, QMS, RIM, and safety workflows.

Analyze the 2026 biotech capital outlook, detailing Blackstone's record $6.3B Life Sciences Fund VI, VC funding trends, biopharma M&A, and market recovery.

Review the 2026 pharma AI vendor landscape. This analysis details 150+ companies using machine learning for drug discovery, clinical trials, and manufacturing.

Examine the FDA approval of Otarmeni, the first gene therapy for OTOF-related congenital hearing loss, and its expedited National Priority Voucher review.